UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Marburg virus

Author
Mike Bray, MD, MPH
Section Editor
Martin S Hirsch, MD
Deputy Editor
Jennifer Mitty, MD, MPH

INTRODUCTION

The virus family Filoviridae contains three genera: Ebolavirus, Cuevavirus, and Marburgvirus. Ebola virus is best known as the causative agent of the widespread epidemic in West Africa that began in late 2013. The Cuevavirus is at present only known through RNA sequences recovered from bats in Spain; no human infections have been reported. This topic reviews the epidemiology, clinical manifestations, treatment, and other aspects of the disease caused by members of the third filovirus genus, Marburgvirus. Detailed discussions of Ebola virus disease are found elsewhere. (See "Epidemiology and pathogenesis of Ebola virus disease" and "Clinical manifestations and diagnosis of Ebola virus disease" and "Treatment and prevention of Ebola virus disease".)

CLASSIFICATION

The filoviruses are nonsegmented, negative-sense, single-stranded RNA viruses that resemble rhabdoviruses and paramyxoviruses in their genome organization and intracellular replication mechanism (see "Clinical manifestations and diagnosis of rabies" and "Measles: Clinical manifestations, diagnosis, treatment, and prevention"). The family name is derived from the Latin "filum," meaning "thread-like," based upon the filamentous structure of the virion.

The genus Marburgvirus contains a single species that consists of two recognized variants, Lake Victoria marburgvirus and Ravn marburgvirus, which show approximately 20 percent overall sequence divergence [1,2]. Despite this variation, the two strains cause an apparently identical disease in humans and laboratory animals, and animals that have received an experimental vaccine based on one variant are cross-protected against the other [3,4]. In contrast, Ebola vaccines do not provide protection against Marburg virus. (See 'Vaccine development' below.)

EPIDEMIOLOGY

Endemic areas — The first recognized outbreak of Marburg virus disease occurred in Germany and Yugoslavia in 1967; the overall fatality rate was 23 percent. This outbreak was a result of the inadvertent importation of infected vervet monkeys (Chlorocebus pygerythrus) from Uganda for use in vaccine production. However, extensive screening of a wide variety of animal species in the region where the macaques had been captured failed to identify a source of the infection [5,6].

Since then, all human infections have occurred in Africa [7-9]. Three cases were seen in South Africa in 1975 [10]. The next recognized outbreak did not take place until 1998, when cases of severe febrile illness were recognized among men working in an abandoned mine in the eastern part of the Democratic Republic of the Congo (DRC) [8]. The largest epidemic, with almost 400 cases, occurred in Angola in 2004. Since then, several individual cases of Marburg virus disease and one further outbreak have been reported in Uganda [2,9,11-13]. Fatality rates among African patients have been as high as 80 to 90 percent [1].

          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Fri Jan 08 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Glaze ER, Roy MJ, Dalrymple LW, Lanning LL. A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the 'Animal Rule'. Comp Med 2015; 65:241.
  2. Towner JS, Khristova ML, Sealy TK, et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol 2006; 80:6497.
  3. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 2006; 80:9659.
  4. Swenson DL, Warfield KL, Larsen T, et al. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines 2008; 7:417.
  5. Monath TP. Ecology of Marburg and Ebola viruses: speculations and directions for future research. J Infect Dis 1999; 179 Suppl 1:S127.
  6. Martini GA. Marburg virus disease. Postgrad Med J 1973; 49:542.
  7. Towner JS, Amman BR, Sealy TK, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 2009; 5:e1000536.
  8. Bausch DG, Nichol ST, Muyembe-Tamfum JJ, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med 2006; 355:909.
  9. Adjemian J, Farnon EC, Tschioko F, et al. Outbreak of Marburg hemorrhagic fever among miners in Kamwenge and Ibanda Districts, Uganda, 2007. J Infect Dis 2011; 204 Suppl 3:S796.
  10. Gear JS, Cassel GA, Gear AJ, et al. Outbreake of Marburg virus disease in Johannesburg. Br Med J 1975; 4:489.
  11. Centers for Disease Control and Prevention (CDC). Imported case of Marburg hemorrhagic fever - Colorado, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:1377.
  12. Timen A, Koopmans MP, Vossen AC, et al. Response to imported case of Marburg hemorrhagic fever, the Netherland. Emerg Infect Dis 2009; 15:1171.
  13. Knust B, Schafer IJ, Wamala J, et al. Multidistrict Outbreak of Marburg Virus Disease-Uganda, 2012. J Infect Dis 2015; 212 Suppl 2:S119.
  14. Centers for Disease Control and Prevention (CDC). Outbreak of Marburg virus hemorrhagic fever--Angola, October 1, 2004-March 29, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:308.
  15. Ogawa H, Miyamoto H, Nakayama E, et al. Seroepidemiological Prevalence of Multiple Species of Filoviruses in Fruit Bats (Eidolon helvum) Migrating in Africa. J Infect Dis 2015; 212 Suppl 2:S101.
  16. Pigott DM, Golding N, Mylne A, et al. Mapping the zoonotic niche of Marburg virus disease in Africa. Trans R Soc Trop Med Hyg 2015; 109:366.
  17. Amman BR, Jones ME, Sealy TK, et al. Oral shedding of Marburg virus in experimentally infected Egyptian fruit bats (Rousettus aegyptiacus). J Wildl Dis 2015; 51:113.
  18. Jones ME, Schuh AJ, Amman BR, et al. Experimental Inoculation of Egyptian Rousette Bats (Rousettus aegyptiacus) with Viruses of the Ebolavirus and Marburgvirus Genera. Viruses 2015; 7:3420.
  19. Amman BR, Carroll SA, Reed ZD, et al. Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog 2012; 8:e1002877.
  20. Mate SE, Kugelman JR, Nyenswah TG, et al. Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med 2015; 373:2448.
  21. Jaax NK, Davis KJ, Geisbert TJ, et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996; 120:140.
  22. Rougeron V, Feldmann H, Grard G, et al. Ebola and Marburg haemorrhagic fever. J Clin Virol 2015; 64:111.
  23. Peters CJ. Marburg and Ebola--arming ourselves against the deadly filoviruses. N Engl J Med 2005; 352:2571.
  24. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4:487.
  25. Mehedi M, Groseth A, Feldmann H, Ebihara H. Clinical aspects of Marburg hemorrhagic fever. Future Virol 2011; 6:1091.
  26. Lin KL, Twenhafel NA, Connor JH, et al. Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques. J Virol 2015; 89:9875.
  27. Messaoudi I, Amarasinghe GK, Basler CF. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol 2015; 13:663.
  28. Martines RB, Ng DL, Greer PW, et al. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol 2015; 235:153.
  29. Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003; 163:2371.
  30. Geisbert TW, Young HA, Jahrling PB, et al. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188:1618.
  31. Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179 Suppl 1:S177.
  32. Mahanty S, Hutchinson K, Agarwal S, et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003; 170:2797.
  33. Geisbert TW, Hensley LE, Gibb TR, et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000; 80:171.
  34. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011; 204 Suppl 3:S810.
  35. Broadhurst MJ, Kelly JD, Miller A, et al. ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study. Lancet 2015; 386:867.
  36. Fusco ML, Hashiguchi T, Cassan R, et al. Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS Pathog 2015; 11:e1005016.
  37. Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 2012; 109:5034.
  38. Heald AE, Charleston JS, Iversen PL, et al. AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. N Engl J Med 2015; 373:339.
  39. Thi EP, Mire CE, Lee AC, et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 2015; 521:362.
  40. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014; 508:402.
  41. Jones SM, Feldmann H, Ströher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786.
  42. Daddario-DiCaprio KM, Geisbert TW, Ströher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367:1399.